Effects of music therapy on anxiety in patients with cancer: study protocol of a randomised controlled trial

Chenbing Sun,1 Shuliu Sang,2 Yunzhe Tang,1 Xiaodie Niu,2 Hwa-Seung Yoo,2 Ping Zhou,4 Hao Liu,5 Yabin Gong,1 Ling Xu1

ABSTRACT

Introduction Although music therapy (MT) has been found to reduce anxiety in patients with cancer and delay tumour progression to some extent, its mechanism of action has not been determined. MT may reduce anxiety by reducing the concentrations of proinflammatory cytokines. The present study was designed to evaluate the effects of MT on anxiety and cytokine levels in patients with cancer.

Methods and analysis This randomised, open, single-centre parallel-controlled trial will randomise 60 patients with malignant tumours who meet the inclusion criteria in a 1:1 ratio to either an MT group or a non-MT (NMT) group. Patients in the MT group will receive emotional nursing care and individualised receptive MT for 1 week, whereas patients in the NMT group will receive emotional nursing care alone. Primary outcomes will include scores on the State-Trait Anxiety Inventory, Distress Thermometer and Hamilton Anxiety Scale. Secondary outcomes will include scores on the Quality of Life Questionnaire C30, serum concentrations of the cytokines interleukin (IL)-1β, tumour necrosis factor-α, IL-2R, IL-4, IL-6, IL-8 and IL-10, serum concentrations of the neurotransmitters 5-hydroxytryptamine, dopamine, norepinephrine, adrenocorticotropic hormone and γ-aminoxybutyric acid, and determination of gut microbiota populations.

Ethics and dissemination On 5 August 2020, the study protocol was approved by the Research Ethics Committee of the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine of the Shanghai University of Traditional Chinese Medicine. The findings of this study will be published in peer-reviewed publications and presented at appropriate conferences.

Trial registration number CTR2000035244.

INTRODUCTION

Current cancer treatments include surgical resection, chemotherapy, targeted therapy and immunotherapy. These treatments, as well as the disease itself, may have adverse psychological effects on patients, including psychological stress reactions and negative emotions such as anxiety and depression, negatively affecting patient quality of life.1 2

A cross-sectional, prospective study suggested that the prevalence of moderate to severe depression in patients with advanced solid tumours was 29.2%.3 The National Comprehensive Cancer Network has classified psychological problems in patients with cancer, such as anxiety and depression, as ‘psychosocial distress’.4 These psychological problems can interfere with patients’ ability to cope with disease and have a negative impact on physical symptoms.4 Reducing anxiety in patients with cancer may therefore have positive effects on their physical and mental health.

Current treatment of cancer-associated anxiety is frequently focused on the primary tumour. Few studies to date have focused on treating anxiety disorders caused by cancer, with even fewer focusing on non-pharmacological treatments. Music therapy (MT) has been defined by the American Music Therapy Association as the ‘clinical and evidence-based use of music interventions to accomplish individualized goals within a therapeutic relationship by a credentialed professional who has completed an approved music therapy program’5. MT includes active methods, such as singing or playing instruments, and receptive methods, which involve the playing of prerecorded music under the guidance of a certified music therapist.6 Over the last few decades, MT has evolved from a specialised field to a method of treating a wide range of conditions,7 including perioperative cancer-associated anxiety8 and anxiety meningiomas.
in patients with breast\textsuperscript{9} and lung\textsuperscript{10} cancer. Evidence has shown that MT could help patients improve their positive attitude toward the disease by regulating their emotions and managing their symptoms.\textsuperscript{11,12} Notably, the Clinical Practice Guidelines on the Evidence-Based Use of Integrative Therapies During and After Breast Cancer Treatment have recommended the application of MT to improve the quality of life and physical functioning of patients with breast cancer.\textsuperscript{13}

The pathophysiological basis of anxiety disorders has not been determined yet, although structural brain abnormalities, neurobiochemical abnormalities and genetic factors are thought to be involved.\textsuperscript{14} The primary mechanisms of concomitant anxiety and depression in patients with tumour are thought to involve an overactive hypothalamic–pituitary–adrenal (HPA) axis, inflammatory mediators and immune factors.\textsuperscript{15,16} Patients with cancer were found more likely to develop depressive symptoms and had a poorer prognosis than healthy individuals. The development and treatment of cancers have been found to increase inflammation mediated by proinflammatory cytokines, such as interleukin (IL)-1, IL-6 and tumour necrosis factor (TNF)-\textalpha. This, in turn, resulted in dysregulation of the HPA axis and led to depression-like behaviours. Conversely, depression was shown to activate the HPA axis, resulting in the release of endogenous glucocorticoids, which caused depressive symptoms in patients with cancer.\textsuperscript{17} The microbiome–gut–brain axis theory has suggested alternative pathways for the pathogenesis of tumour anxiety, especially anxiety associated with intestinal cancers. The intestinal flora were shown to regulate brain function via neural pathways involving the enteric and vagus nerves; endocrine pathways involving intestinal hormones; and immune pathways involving immune cells and cytokines, thereby affecting mood, behaviour and neuroinflammation.\textsuperscript{18} Many gut microbiota, including Candida, Streptococcus, Enterococcus and Bacillus spp and Escherichia coli, have been shown to produce neurotransmitters, such as 5-hydroxytryptamine (5-HT).\textsuperscript{19–21}

In addition to directly influencing tumour development by regulating angiogenesis and the tumour growth microenvironment, chronic stress can indirectly affect tumour development by altering human hormone levels.\textsuperscript{22} MT may affect tumour related anxiety by altering neuroendocrine factors and factors associated with the cellular immune system and the gut–brain axis. For example, music was shown to modulate salivary stress markers and physiological markers of the HPA axis\textsuperscript{23} and to reduce depressive symptoms.\textsuperscript{24} Exposure of mice to music was found to alter the expression of brain-derived neurotrophic factor (BDNF) in the hypothalamus.\textsuperscript{25} BDNF has been associated with tumour development,\textsuperscript{26,27} with high levels of BDNF expression in cancer indicating poor prognosis.\textsuperscript{28,29} In depressed mice, MT increased serum 5-HT levels, decreased monoamine oxidase levels in hippocampal tissue and malondialdehyde levels in liver tissue, and relieved depression.\textsuperscript{30} Improved mood has been shown to reduce anxiety and depression by influencing metabolism and ultimately inhibiting tumour development.\textsuperscript{31} However, despite evidence showing that MT can reduce anxiety in oncology patients and delay tumour progression to some extent, its exact mechanism of action is still unknown.

The present study will evaluate the effects on anxiety of patients with cancer of receptive and individualised MT under the guidance of a music therapist. This randomised controlled study will assess the ability of individualised MT to reduce cancer-related anxiety by analysing anxiety-related scales after MT. In addition, this study will evaluate cytokine levels, gut microbiota and neurotransmitters to explore the clinical evaluation of the efficacy of MT.

**MATERIALS AND METHODS**

**Study design**

This randomised controlled trial (RCT) will enrol 60 patients with cancer who are experiencing cancer-related anxiety. Patients will be randomly divided 1:1 into two groups, with patients in the MT group receiving emotional nursing care and individualised receptive MT (MT group) and patients in the non-MT group receiving emotional nursing care alone (NMT group) for 1 week. The study will be performed at Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, between 10 December 2022 and 31 December 2023. Figure 1 shows the design of the trial based on standard protocol items. The Standard Protocol Items: Recommendations for Interventional Trials checklist is shown in online supplemental appendix 1.

**Inclusion criteria**

Subjects will be included if they (1) have a malignant tumour, as confirmed by histopathology or cytology; (2) have been treated for cancer-related anxiety or cancer itself for ≥2 months and ≤1 year; (3) meet the standard criteria for anxiety, including Hamilton Anxiety Scale (HAMA) scores ≥7 and ≤28 and State-Trait Anxiety Inventory (STAI) sores ≥20 and ≤80; (4) are aged 18–74 years, with no gender restrictions; (5) do not smoke or drink; (6) do not have psychiatric symptoms; (7) hear normally; (8) have normal heart, liver, kidney and blood test results, with all other vital signs being normal; (9) have not taken anti-anxiety medications within 4 weeks prior to study entry; (10) have an expected survival time >6 months and (11) provide written informed consent to study participation.

**Exclusion criteria**

Subjects will be excluded if they (1) are currently participating in other clinical studies or clinical trials; (2) have other serious diseases, such as infection, liver or kidney failure, making them unable, in the opinion of the project leader or researchers, to tolerate the treatment regimen of this study; (3) have primary or metastatic brain tumour, as confirmed clinically or radiologically; (4) are pregnant or...
lactating women; (5) have received MT within 3 months prior to the study; (6) are taking anxiety medications or medications that can affect anxiety.

**Rejection, suspension and shedding criteria**

Patients will be discontinued from the study if they (1) are found not to meet the above inclusion criteria or meet the exclusion criteria; (2) show poor compliance or fail to follow up as required; (3) have incomplete medical records; (4) withdraw voluntarily from the study; (5) are regarded as unsuitable to continue the study due to serious deterioration of disease, severe complications or special physiological changes; or (6) are regarded by the investigator as unsuitable to continue the study. In addition, patients in the control group will be discontinued if they listen to music during the study period.

**Participant recruitment**

This study aims to include 60 patients with cancer who are experiencing cancer-related anxiety. Patients at the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine will be recruited by posting advertisements on the hospital’s website and on posters. These advertisements will include brief descriptions of the study aims, requirements and methods. All participants will provide written informed consent. Patients will be recruited from December 2022 to December 2023.
Informed consent
All study processes will be explained to participants prior to the start of the study. Participants will also be informed that their participation in this trial is entirely voluntary and that they can opt out at any time. Each participant will be required to sign a written informed consent form before receiving any intervention. The informed consent is shown in online supplemental appendix 2.

Randomisation and concealment of allocation
Patients will be randomly assigned to the treatment and control groups in a 1:1 ratio at the time of enrolment. A set of randomised numbers will be generated by SPSS V22.0 software, with each number randomised into opaque envelopes. The order in which patients enter the study will be determined by the grouping of the corresponding envelopes allocated by the researcher.

Intervention
Patients in the NMT group will receive emotional nursing care but not be allowed to receive any treatment for anxiety or music listening. Emotional nursing care includes symptoms inquiry and timely communication when emotional distress occurs. Inquiry and communication will be carried out while the MT group performs the treatment. If treatment is required due to worsening anxiety, it will be recorded and excluded. Patients who requested to participate in the music therapy sessions randomly assigned to the NMT group will receive the same MT as the MT group after completing the prescribed follow-up time (D14 and D28).

Patients in the MT group will receive individualised receptive MT supervised by a music therapist, along with required anti-cancer medications. Prior to starting MT, patients in the MT group will be introduced to the MT process for 5–10 min by the music therapist. The treatment room will be soundproofed, with patients in a resting or sitting position with eyes closed and relaxed. Prior to MT, patients in the MT group will be exposed to various types of music to determine their preferences. The repertoire for MT, which is nature-based sound, lasting 10–15 min, will be composed by the Department of Music Engineering of Shanghai Conservatory of Music. After recording each patient’s music preferences during playback, no more than three music clips from each genre will be chosen for individualised music clips of total length about 20 min, increasing individual patient comfort and orientation and reducing anxiety. Subsequently, the music therapist will play the personalised music clip created for 20 min, at 15:00–16:00, once a day for 1 week. Studies have shown that intervention 1–3 days with MT 30–60 min per day is effective for depression and anxiety of various patients with cancer.32–34 Simultaneously, another music therapist will use a psychoeducational approach in conjunction with verbal instructions. The psychoeducational approach in conjunction with verbal instruction includes: (1) informing the patient of the purpose and duration of the treatment; (2) adjusting the appropriate volume; (3) instructing the patient how to adjust breathing and relax methodically from head to feet to the rhythm of the music. Conditions for music therapy will include: (1) no bright light interference; (2) the patient in a resting or inactive state; and (3) music played through speakers at a volume controlled between 45% and 65%.

All participants will be required to complete STAI, Distress Thermometer (DT), HAMA and Quality of Life Questionnaire C30 (QLQ-C30) instruments on the day before and the day after treatment, as well as 14 and 28 days after treatment. The total scores of these items will be calculated and their differences in the MT and NMT groups will be compared. Blood samples will be collected for ELISA analysis of cytokine levels (serum IL-1β, TNF-α, IL-2R, IL-4, IL-6, IL-8 and IL-10) and neurotransmitter levels (5-HT, dopamine, norepinephrine, adrenocorticotropic hormone and γ-aminobutyric acid). Gut microbiota will be collected on the day after treatment, then be analysed by 16sRNA. Changes in primary disease condition will also be recorded. Music intervention flow is shown in table 1.

Data collection
Members of the Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine will collect and evaluate data from inpatients at screening and baseline, as well as during and after intervention and at follow-up periods.

Enrolment and baseline
Patients will be screened at admission using inclusion and exclusion criteria. Information collected from patients who qualified will include important demographic characteristics, such as age, sex, education and marital status, and general clinical characteristics, including type of disease, disease stage, surgical history, current treatment and previous treatment. All included patients will complete the STAI, DT, HAMA and QLQ-C30. The STAI consists of 40 items, each of which is graded on a 4-point scale with S-AI levels of 1 for not at all, 2 for somewhat, 3 for moderately and 4 for very significantly; and T-AI levels of 1 for almost never, 2 for occasionally, 3 for frequently and 4 for almost always; with 10 reverse scores. Reverse scoring will be given in order 4, 3, 2 and 1 to calculate cumulative scores for the S-AI and T-AI scales, with a minimum score of 20 and a maximum score of 80. The total S-AI score will reflect the severity of each subject’s current anxiety symptoms, whereas the total T-AI score will reflect each subject’s consistent or usual anxiety, with higher scores indicating more severe anxiety,35 36 and no specific cut-offs exist.6 Referring to previous studies, we defined ‘high anxiety’ as a score of STAI ≥40.37 The DT uses distress scores to determine each patient’s level of psychological distress which includes a Visual Analogue Scale score and a problem list.38–40 The HAMA consists of 14 items, with symptoms graded on a 5-point scale from
0 to 4, with 0 indicating no symptoms; 1 indicating mild symptoms; 2 indicating moderate symptoms; 3 indicating severe symptoms; and 4 indicating extremely severe symptoms. The cut-off value for HAMA was a total score of 14. Total scores ≥29, ≥21, ≥14, ≥7 and <7 were indicative of severe anxiety, significant pressure, anxiety, probable anxiety and no anxiety, respectively.41 The QLQ-C30, which will be used to assess quality of life, has shown high...
The primary and secondary outcomes are shown in Table 3.

### Outcome measures

#### Primary outcomes

- **Assessment of the effects of MT on symptoms of anxiety in patients with cancer with anxiety**
  - STAI will be used to detect transient anxiety and stable anxiety tendency in patients with cancer
  - HAMA will be used to evaluate the severity of anxiety symptoms in patients with cancer
  - DT will be used to determine the level of psychological distress in patients with cancer

#### Secondary outcomes

- **Assessment of the effects of MT on quality of life and immune-related blood indices in patients with cancer with anxiety**
  - QLQ-C30 will be used to assess the quality of life and overall health status of patients with cancer
  - Blood index and physiological indicators will be used to assess changes in serum concentrations of cytokines (IL-1β, TNF-α, IL-2R, IL-4, IL-6, IL-8 and IL-10) and neurotransmitters (5-HT, DA, NE, ACTH and GABA) in patients with cancer with anxiety before and after treatment
  - Gut microbiota will be collected to compare the differences in diversity, enterobacteriaceae and short-chain fatty acids

ACTH, adrenocorticotrophic hormone; DA, dopamine; DT, Distress Thermometer; GABA, γ-aminobutyric acid; HAMA, Hamilton Anxiety Scale; 5-HT, 5-hydroxytryptamine; IL, interleukin; NE, norepinephrine; QLQ-C30, Quality of Life Questionnaire C30; STAI, State-Trait Anxiety Inventory; TNF-α, tumour necrosis factor-α.

### Adherence and follow-up

During the treatment period, patients will be hospitalised at Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, to facilitate follow-up; patients unable to be followed up as inpatient will undergo telephone follow-up by a research assistant. Patient schedules are shown in Table 2.

### Outcome measures

The primary and secondary outcomes are shown in Table 3.

### Quality control

To ensure the accuracy of the experiments, research assistants will review study documents, informed consent forms, case report forms (CRFs) and data records on a regular basis.

### Data management

The team leader and research assistant will review the CRFs and scales before handing them over to data management staff for data entry and administration. The original CRFs and all scales (including consent forms) will be kept at the Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine.

### Sample size

Based on previous studies, the level of STAI improvement will be regarded as the main indicator of efficacy, with differences of 5.43 regarded as the primary outcome, with a unilateral p=0.05. Sample size calculation will be done with PASS V.15.0 software using the formula:

\[
n_1 = n_2 = \frac{u_{a/2} \sqrt{2p(1-p)} + u_{a/2} \sqrt{p(1-p)} + u_{a/2} \sqrt{p(1-p) + p(1-p)}}{(p_1 - p_2)^2}
\]

The minimum total sample size was calculated to be 48 patients. Including a 20% withdrawal rate, the minimum total sample size was 60 patients, or 30 in each group based on 1:1 randomisation.

### Statistical analysis

Normally distributed continuous variables will be compared by t-tests and non-normally distributed continuous variables by Mann-Whitney rank-sum tests. Categorical variables will be compared by χ² tests. SPSS V.22.0 will be used to generate a normal probability graph and perform a hypothesis test to check whether the observed values obeyed a normal distribution. Individual data points will be superimposed on a box-plot for calculations. The results of anxiety correlation scales and ELISA will be compared by t-tests or Mann-Whitney rank-sum tests according to whether the normal distribution
is met or not. The results of 16sRNA will be classified by the RDP reference database (http://www.mothur.org/wiki/RDP_reference_files) to calculate the relative abundance of microbial communities at different levels. Then, the differences between samples (groups) will be calculated by Principal Component Analysis, Principal Coordinates Analysis, Non-Metric Multi-Dimensional Scaling, Unweighted Pair-group Method with Arithmetic Means and Beta Diversity Index Inter-group Difference Analysis. All statistical analyses will be performed by SPSS V.22.0 software, with p<0.05 considered statistically significant. Patients who used other drugs or therapies on cancer will be stratified in statistical analysis.

**Ethical issues**
The study will adhere to the Helsinki Declaration and the Ethical Guidelines for Clinical Research. The study protocol has been approved by the Research Ethical Committee of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine (approval number: 2019092).

**DISCUSSION**

Anxiety and depression are associated with cancer mortality and survival rates.43 The increased focus on quality of life of patients with cancer has increased interest in their emotional symptoms. MT may reduce anxiety and depression, and improve the quality of life of patients with cancer.44–46 MT is a risk-free, flexible operation and cost-effective intervention that may improve anxiety in patients with cancer. The RCT described in this study will test whether this non-pharmacological intervention can reduce anxiety in patients with cancer. Findings of this study may serve as a reference for trials determining whether other non-pharmacological methods could improve anxiety symptoms in oncology patients.

A major strength of the present trial is its method of intervention, in which individual patients are exposed to a personalised music clip based on each patient’s preference. Outcomes will be measured using the STAI, DT, HAMA and QLQ-C30 instruments. HAMA scores are measured by physicians, making them more objective. STAI can respond to both short-term and long-term emotional traits. The STAI and HAMA scales will therefore be combined to reduce bias and increase the reliability of the results. Moreover, this study will measure the levels of neurotransmitters, gut microbiota and cytokines in patients with tumour to explore the mechanisms by which MT improves anxiety in patients with tumour. A meta-analysis reported that high levels of IL-8 and IL-6 were significantly associated with the prognosis of patients with cancer treated with immune checkpoint inhibitors.47 Moreover, serum IL-6 levels can be used as a biomarker to predict the outcome of treatment with antidepressants.48 A case–control study found that faecal microbiota signatures differed in patients with gastrointestinal cancer with and without anxiety and depression.49 The gut–brain–microbiota axis could modulate depression and anxiety induced by chronic stress through ileal immune regulation.50 In addition, MT could increase salivary immunoglobulin A levels and reduce cortisol levels of patients with cancer.51 MT can significantly increase natural killer cell count and activity.52 Therefore, we will assess the effects of MT on the efficacy of immunotherapy in patients with cancer in the future studies.

This study, however, is still subject to some limitations. The major limitation is the single-centre nature of this trial, which may limit the generalisability of study results. In addition, the intervention period will be only 1 week, which may be too short to determine the effects of MT on immune function and gut microbiota. Future studies should be designed to test whether longer periods of MT are of greater benefit in patients with cancer.

**Trial status**
The first participant will be enrolled in December 2022 and the study is expected to end in December 2023.

**Author affiliations**

1Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
2School of Acupuncture-Moxibustion and Tuina, Shanghai University of Traditional Chinese Medicine, Shanghai, China
3Department of Integrative Oncology, East West Cancer Center, Seoul Korea Medicine Hospital, Seoul, Korea (the Republic of)
4Department of Music Education, Shanghai Conservatory of Music, Shanghai, China
5Department of Music Engineering, Shanghai Conservatory of Music, Shanghai, China

**Acknowledgements**
The authors thank all subjects who will participate in this randomised controlled trial.

**Contributors**

CS and SS designed the study. YT, XN and H-SY wrote the manuscript. PZ and HL developed the details of music therapy. YG and LX recruited the patients and refined the protocol. All authors approved the final version.

**Funding**

Sponsored by the Shanghai Sailing Program (no. 21YF1448200), the National Natural Science Foundation of China (no. 82074339), the Natural Science Foundation of Shanghai, China (no. 20ZR1459400), the fifth batch of national TCM clinical outstanding talents training program (RNM410.17.06), the TCM Evidence-based Capacity Building Project of State Administration of Traditional Chinese Medicine (no. 2019KZZX-2L004), the Shanghai Shenhong Hospital Development Center Clinical 3-year action plan project (no. SHMC2020CR1052B), the Project of Shanghai Science and Technology Commission (no. 20YF1902000), and the Traditional Chinese medicine dominant disease cultivation project (zybz-2017009).

**Competing interests**

None declared.

**Patient and public involvement**

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication**

Not required.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Supplemental material**

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is
REFERENCES


# SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents

<table>
<thead>
<tr>
<th>Section/item</th>
<th>Item No</th>
<th>Description</th>
<th>Addressed on page number</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Administrative information</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Title</td>
<td>1</td>
<td>Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym</td>
<td>1</td>
</tr>
<tr>
<td>Trial registration</td>
<td>2a</td>
<td>Trial identifier and registry name. If not yet registered, name of intended registry</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>All items from the World Health Organization Trial Registration Data Set</td>
<td>None</td>
</tr>
<tr>
<td>Protocol version</td>
<td>3</td>
<td>Date and version identifier</td>
<td>1</td>
</tr>
<tr>
<td>Funding</td>
<td>4</td>
<td>Sources and types of financial, material, and other support</td>
<td>11</td>
</tr>
<tr>
<td>Roles and responsibilities</td>
<td>5a</td>
<td>Names, affiliations, and roles of protocol contributors</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>5b</td>
<td>Name and contact information for the trial sponsor</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>5c</td>
<td>Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>5d</td>
<td>Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)</td>
<td>None</td>
</tr>
</tbody>
</table>

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance on the information contained herein or provided as a result of the author(s) placing this supplemental material which has been supplied by the author(s).
Introduction

Background and rationale

6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention 2-3

6b Explanation for choice of comparators 3

Objectives

7 Specific objectives or hypotheses 3

Trial design

8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) 3

Methods: Participants, interventions, and outcomes

Study setting

9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained 4

Eligibility criteria

10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) 4

Interventions

11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered 5

11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) 5

11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) 5

11d Relevant concomitant care and interventions that are permitted or prohibited during the trial 5
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcomes</td>
<td>8-9</td>
<td>Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended.</td>
</tr>
<tr>
<td>Participant timeline</td>
<td>4</td>
<td>Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure).</td>
</tr>
<tr>
<td>Sample size</td>
<td>9</td>
<td>Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations.</td>
</tr>
<tr>
<td>Recruitment</td>
<td>4-5</td>
<td>Strategies for achieving adequate participant enrolment to reach target sample size.</td>
</tr>
<tr>
<td><strong>Allocation:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sequence generation</td>
<td>5</td>
<td>Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions.</td>
</tr>
<tr>
<td>Allocation concealment mechanism</td>
<td>5</td>
<td>Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned.</td>
</tr>
<tr>
<td>Implementation</td>
<td>5</td>
<td>Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions.</td>
</tr>
<tr>
<td>Blinding (masking)</td>
<td>None</td>
<td>Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how.</td>
</tr>
</tbody>
</table>
17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial

Methods: Data collection, management, and analysis

Data collection methods

18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol

18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols

Data management

19 Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol

Statistical methods

20a Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol

20b Methods for any additional analyses (eg, subgroup and adjusted analyses)

20c Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)

Methods: Monitoring

Data monitoring

21a Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed

None

6

6-7

9

10

10

10

9
<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>21b</td>
<td>Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial</td>
<td>4</td>
</tr>
<tr>
<td>Harms</td>
<td>Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct</td>
<td>4</td>
</tr>
<tr>
<td>Auditing</td>
<td>Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor</td>
<td>None</td>
</tr>
<tr>
<td>Ethics and dissemination</td>
<td>Plan for seeking research ethics committee/institutional review board (REC/IRB) approval</td>
<td>10</td>
</tr>
<tr>
<td>Research ethics approval</td>
<td>Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)</td>
<td>None</td>
</tr>
<tr>
<td>Consent or assent</td>
<td>Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)</td>
<td>9</td>
</tr>
<tr>
<td>Confidentiality</td>
<td>How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial</td>
<td>9</td>
</tr>
<tr>
<td>Declaration of interests</td>
<td>Financial and other competing interests for principal investigators for the overall trial and each study site</td>
<td>11</td>
</tr>
<tr>
<td>Access to data</td>
<td>Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators</td>
<td>12</td>
</tr>
<tr>
<td>Section</td>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Ancillary and post-trial care</td>
<td>30</td>
<td>Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation</td>
</tr>
<tr>
<td>Dissemination policy</td>
<td>31a</td>
<td>Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions</td>
</tr>
<tr>
<td></td>
<td>31b</td>
<td>Authorship eligibility guidelines and any intended use of professional writers</td>
</tr>
<tr>
<td></td>
<td>31c</td>
<td>Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code</td>
</tr>
<tr>
<td>Appendices</td>
<td>32</td>
<td>Model consent form and other related documentation given to participants and authorised surrogates</td>
</tr>
<tr>
<td>Biological specimens</td>
<td>33</td>
<td>Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable</td>
</tr>
</tbody>
</table>

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported license.
Informed Consent of “Effects of music therapy on anxiety in cancer patients: A randomized controlled trial”

**Informed Consent • Informed Notice page**

**Project Name:** Effects of music therapy on anxiety in cancer patients with cancer: study protocol of a randomised controlled trial  
**Research Unit:** Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine  
**Principal:** Ling Xu Yabin Gong Chenbing Sun  
**Address:** 110 Ganhe Road, Shanghai, China

Dear patient,

Your doctor has diagnosed you with a malignant neoplastic disease. We will invite you to participate in a randomized controlled trial of the effects of music therapy on anxiety in cancer patients. Before you decide whether or not to participate in the study, please read the following as carefully as possible to help you understand the study and why it is being conducted, the procedure and duration of the study, and the benefits, risks, and discomfort that may result from participating in the study. If you wish, you can also discuss it with your relatives and friends, or ask your doctor for an explanation to help you make a decision.

1. **Research Background:**

Current cancer treatments include surgical resection, chemotherapy, targeted therapy and immunotherapy. These treatments, as well as the disease itself, may have adverse psychological effects on patients, including psychological stress reactions and negative emotions such as anxiety and depression, negatively affecting patient quality of life.

Current treatment of cancer-associated anxiety is frequently focused on the primary tumor. Few studies to date have focused on treating anxiety disorders caused by cancer, with even fewer focusing on non-pharmacological treatments. Music therapy has been defined by the American Music Therapy Association (AMTA) as the “clinical and evidence-based use of music interventions to accomplish individualized goals within a therapeutic relationship by a credentialed professional who has completed an approved music therapy program”. Over the last few decades, music therapy has evolved from a specialized field to a method of treating a wide range of conditions, including perioperative cancer-associated anxiety and anxiety in patients with breast and lung cancer. The pathophysiological basis of anxiety disorders has not yet been determined, although structural brain abnormalities, neurobiochemical abnormalities, and genetic factors are thought to be involved. The primary mechanisms of concomitant anxiety and depression in tumor patients are thought to involve an overactive hypothalamic-pituitary-adrenal (HPA) axis, inflammatory mediators, and immune factors.

2. **Purpose of research:**

This randomized controlled study will assess the ability of individualized music therapy to reduce cancer-related anxiety in patients by analyzing anxiety-related scales after music therapy. In addition, this study will evaluate cytokine...
concentrations, gut microbiota and neurotransmitter-related indicators to explore the link their associations in cancer patients. The study will be conducted at Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, and 60 participants are expected to participate voluntarily. The Ethics Committee of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine has considered that the study is in line with the principles of the "Measures for Ethical Review of Biomedical Research Involving Humans" and the "Declaration of Helsinki", and in line with medical ethics.

3. Inclusion criteria

Subjects will be included if they (1) have a malignant tumor, as confirmed by histopathology or cytology; (2) have been treated for cancer-related anxiety or cancer itself for ≥ 2 months and ≤ 1 year; (2) meet the standard criteria for anxiety, including HAMA scores ≥ 7 and ≤ 28 and STAI sores ≥ 20 and ≤ 80; (3) are aged 18 to 74 years, with no gender restrictions; (4) have no history of other mental disorders and do not smoke or drink; (5) are conscious, behave and hear normally, and do not have a professional music background; (6) have normal heart, liver, kidney, and blood test results, with all other vital signs being normal; (7) have not taken anti-anxiety medications within four weeks prior to study entry; (8) have an expected survival time > 6 months; and (8) provide written informed consent to study participation.

4. Exclusion criteria

Subjects will be excluded if they (1) are currently participating in other clinical studies or clinical trials; (2) have other serious diseases, such as infection, liver or kidney failure, making them unable, in the opinion of the project leader or researchers, to tolerate the treatment regimen of this study; (3) have primary or metastatic brain tumors, as confirmed clinically or radiologically; (4) are pregnant or lactating women; (5) have received music therapy within 3 months prior to the study; or (6) are taking anxiety medications or medications that can affect anxiety.

5. Rejection, suspension and shedding criteria

Patients will be discontinued from the study if they (1) are found not to meet the above inclusion and exclusion criteria; (2) show poor compliance or fail to follow up as required; (3) have incomplete medical records; (4) withdraw voluntarily from the study; (5) are regarded as unsuitable to continue the study due to serious deterioration of disease, severe complications or special physiological changes; or (6) are regarded by the investigator as unsuitable to continue the study. In addition, patients in the control group will be discontinued if they listen to music during the study period.

6. If you participate in the study, you will need to do the following work:

(1) Before you are enrolled in the study, you will undergo the following tests to determine whether you can participate in the study. Your doctor will ask you, take your medical history, and perform a physical examination. You need to do the cytokines IL-1β, TNF-α, IL-2R, IL-4, IL-6, IL-8 and IL-10, serum concentrations of the neurotransmitters 5-HT, DA, NE, ACTH and GABA, and determination of gut microbiota populations.

(2) If you meet the eligibility criteria, you will be studied according to the following
Informed Consent of “Effects of music therapy on anxiety in cancer patients: A randomized controlled trial”

steps:
At the beginning of the study, a random number will determine whether you will be placed in the control or treatment group. Patients in the study each had a 50% chance of being assigned to one of the two different treatment groups. Neither you nor your doctor can know and choose any treatment in advance. The treatment will last for 1 week.

7. Intervention
Patients in the NMT group will receive emotional nursing care but not be allowed to receive any treatment for anxiety. If treatment is required due to worsening anxiety, it will be recorded and excluded. Patients who requested to participate in the music therapy sessions randomly assigned to the NMT group will receive the same music therapy as the MT group after completing the prescribed follow-up time.

Patients in the MT group will receive individualized receptive music therapy supervised by a music therapist, along with routine nursing care as well as required medications. Prior to starting music therapy, patients in the MT group will be introduced to the music therapy process for 5-10 minutes by the music therapist. The treatment room will be soundproofed, with patients in a resting or sitting position with eyes closed and relaxed.

Prior to music therapy, patients in the MT group will be exposed to various types of music to determine their preferences. The repertoire for music therapy which is nature-based sound, lasting 10-15 minutes, will be composed by the Department of Sound Engineering of Shanghai Conservatory of Music. After recording each patient's music preferences during playback, no more than three music clips from each genre will be chosen for individualized music clips of total length about 20 minutes, increasing individual patient comfort and orientation and reducing anxiety. Subsequently, the music therapist will play the personalized music clip created for 20 minutes, once a day for one week. Simultaneously, another music therapist will use a psycho-educational approach in conjunction with verbal instructions. Conditions for music therapy will include: (1) no bright light interference; (2) the patient in a resting or inactive state; and (3) music played through speakers at a volume controlled between 45-65%.

All participants will be required to complete State-Trait Anxiety Inventory (STAI), Distend Thermometer (DT), Hamilton Anxiety Scale (HAMA) and Quality of Life Questionnaire C30 (QLQ-C30) instruments on the day before and the day after treatment, as well as 14 and 28 days after treatment. The total scores of these items will be calculated and their differences in the MT and NMT groups will be compared. Blood samples will be collected for analysis of cytokine levels (serum IL-1β, TNF-α, IL-2R, IL-4, IL-6, IL-8 and IL-10), neurotransmitter levels (5-HT, DA, NE, ACTH and GABA) and gut microbiota on the day after treatment. Changes in primary disease condition will also be recorded.

8. Other matters requiring your cooperation
You must follow your doctor's instructions for treatment. If you need any other treatment, please contact your doctor in advance.

9. Possible benefits of participating in a study
Informed Consent of “Effects of music therapy on anxiety in cancer patients: A randomized controlled trial”

You and society will probably benefit from this research. Such benefits include the possibility that your condition may or may not improve. In addition, this study may help evaluate the effectiveness of music therapy in relieving cancer patients with anxiety, and form a comprehensive music therapy program for tumor patients with anxiety symptoms, which can be used for other patients with similar conditions.

10. Possible adverse reactions, risks, discomfort and inconvenience of participating in the study

The treatment process may have emotional abnormalities and other adverse reactions. We will strictly regulate the treatment process and operation of music therapy to avoid the above things.

If you experience any discomfort during the study, or if you experience any new changes in your condition, or if anything unexpected, whether or not it is related to your treatment, you should inform your doctor promptly and he/she will make a judgment and take medical treatment.

The researchers will do their best to prevent and treat the adverse reactions that may result from this study. If an adverse event occurs during a clinical trial, a committee of medical experts will determine whether it is related to the treatment. As determined by the expert committee, the adverse event is related to the treatment, and the research group will provide the cost of treatment and corresponding financial compensation for the trial-related damage.

During the study period, you need to go to the hospital for follow-up visit on time and do some physical and chemical examinations such as interleukin energy, which may cause you trouble or inconvenience.

11. Qualified tuition and related expenses

The costs of the studies related to this study that you undergo during your study are at your own expense, but these tests themselves are also required for the assessment of your primary disease. Tumor related immune indicators (cytokines and neurotransmitters) and gut microbiota were detected once before and after treatment.

12. Is personal information confidential?

Your medical records (research record / CRF, physical and chemical examination report, etc.) will be completely stored in the hospital, and the doctor will record the results of the laboratory examination in your outpatient medical record. The investigator, sponsor representative, and ethics committee will be granted access to your medical records. Any public report on the results of this study will not disclose your personal identity. We will make every effort to protect the privacy of your personal medical data to the extent permitted by law.

Your biological specimen will be kept in the hospital laboratory as required. In addition to this study, it may be used again in other studies in the future. You may now refuse to use your biological specimens for research other than this study.

13. How to get more information?

You may ask any questions about this study at any time. Your doctor will give you his/her phone number so he/she can answer your questions.

Your doctor will inform you if there is any important new information during the study that may affect your willingness to continue participating in the study.
14. **You can voluntarily opt in and out of the study**
Participation in the study is entirely up to you. You may decline to participate in the study or withdraw from the study at any time during the study without affecting your relationship with your physician or any loss of medical or other benefits. Your physician or investigator may, in your best interest, discontinue you from the study at any time.
If you do not participate in the study or drop out of the study, there are many alternative treatments, such as anti-anxiety medications. You do not have to choose to participate in this study in order to treat your disease.

15. **What should we do now?**
It is up to you to decide whether to participate in this study. You can discuss it with your family or friends before making a decision.
Before you make the decision to participate in a study, please ask your doctor as many questions as possible until you fully understand the study. Thank you for reading the above. If you decide to participate in this study, please let your doctor know and he/she will arrange everything for you.

16. The experimental protocol is approved by the Ethics Committee of Shanghai University of Traditional Chinese Medicine. Subjects can directly consult or complain to the Ethics Committee if there is any question or situation during the experiment.

**Please keep this information.**
Informed Consent of “Effects of music therapy on anxiety in cancer patients: A randomized controlled trial”

Informed Consent · Signature page

Clinical Research Project Name: Effects of music therapy on anxiety in cancer patients: A randomized controlled trial

Sponsor: Ling Xu  Yabin Gong  Sunchenbing

Trial registration number: CTR2000035244

Declaration of consent

I have read the above introduction about this study and fully understand the full contents of the informed consent form, and I have had the opportunity to discuss and ask questions about this study with my doctor. All my questions were answered satisfactorily.

I am aware of the possible risks and benefits of participating in this study. I understand that participation in the study is voluntary, I confirm that I have had sufficient time to consider it, and I understand that:

- I can always ask the doctor for more information.
- I can withdraw from the study at any time without discrimination or retaliation, and my medical treatment and rights will not be affected.
- I also know that if I drop out of the study, especially due to side effects, I need to tell my doctor about any changes in my condition and complete the appropriate physical and physical examination, which will be very beneficial to me and the whole study.
- If I need to take any other medication due to a change in my condition, I will either consult my doctor beforehand or tell my doctor afterwards.
- I allow the Ethics Committee or the sponsor's representative to access my research data.
- I consent to or refuse to use my medical records and biological specimens for research other than this study.
- I will be provided with a signed and dated copy of the informed consent. In the end, I decided to agree to participate in the study and try to follow the doctor's advice.

Date of subject's signature (handwritten)

Subject's contact Number

Subject's legal guardian's signature (if necessary), (handwritten) Date

Guardian's contact Number

Doctor's statement

I confirm that I have explained the details of the trial, including its powers and possible benefits and risks, and have given the patient a signed copy of the informed consent.

The investigator (informing subject) signed (handwritten) Date

Researcher contact Number